How many drugs treat Pseudobulbar affect?

Drug Landscape tracks 2 marketed treatments for Pseudobulbar affect (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/pseudobulbar-affect.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pseudobulbar affect — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pseudobulbar affect (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pseudobulbar affect, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Delsym	dextromethorphan	Generic (originally Roche)	Antitussive (non-opioid)	Taste receptor type 2 member 46, Solute carrier family 22 member 1, Cytochrome P450 2D6		1958-01-01
Quinidine Gluconate	QUINIDINE SULFATE	Eli Lilly	Antiarrhythmic	Muscarinic acetylcholine receptor M2		1950-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Eli Lilly · 1 drug in Pseudobulbar affect
Generic (originally Roche) · 1 drug in Pseudobulbar affect

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pseudobulbar affect:

Cite this brief

Drug Landscape (2026). Pseudobulbar affect — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pseudobulbar-affect. Accessed 2026-06-10.

Pseudobulbar affect full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing